3-Ketone-4,6-diene ceramide analogs exclusively induce apoptosis in chemo-resistant cancer cells.

[1]  A. Huwiler,et al.  Effective inhibition of acid and neutral ceramidases by novel B-13 and LCL-464 analogues. , 2013, Bioorganic & medicinal chemistry.

[2]  A. Bielawska,et al.  LCL124, a Cationic Analog of Ceramide, Selectively Induces Pancreatic Cancer Cell Death by Accumulating in Mitochondria , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[3]  K. P. Bhabak,et al.  Novel amide- and sulfonamide-based aromatic ethanolamines: effects of various substituents on the inhibition of acid and neutral ceramidases. , 2012, Bioorganic & medicinal chemistry.

[4]  S. Morad,et al.  Ceramide–Antiestrogen Nanoliposomal Combinations—Novel Impact of Hormonal Therapy in Hormone-Insensitive Breast Cancer , 2012, Molecular Cancer Therapeutics.

[5]  K. Khoo,et al.  Ceramide Glycosylation by Glucosylceramide Synthase Selectively Maintains the Properties of Breast Cancer Stem Cells* , 2012, The Journal of Biological Chemistry.

[6]  F. Simbari,et al.  3-Deoxy-3,4-dehydro analogs of XM462. Preparation and activity on sphingolipid metabolism and cell fate. , 2012, Bioorganic & medicinal chemistry.

[7]  B. Beckman,et al.  Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. , 2012, Bioorganic & medicinal chemistry letters.

[8]  A. Singh,et al.  3,4-Disubstituted oxazolidin-2-ones as constrained ceramide analogs with anticancer activities. , 2011, Bioorganic & medicinal chemistry.

[9]  L. Rhodes,et al.  Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. , 2011, Journal of molecular endocrinology.

[10]  Steven Elliott,et al.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 , 2011, Cancer biology & therapy.

[11]  A. Bielawska,et al.  Synthesis, NMR characterization and divergent biological actions of 2'-hydroxy-ceramide/dihydroceramide stereoisomers in MCF7 cells. , 2010, Bioorganic & medicinal chemistry.

[12]  L. Rhodes,et al.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. , 2010, Endocrinology.

[13]  Jiawang Liu,et al.  Novel anti-viability ceramide analogs: design, synthesis, and structure-activity relationship studies of substituted (S)-2-(benzylideneamino)-3-hydroxy-N-tetradecylpropanamides. , 2010, Bioorganic & medicinal chemistry.

[14]  S. Pyne,et al.  Sphingosine 1-phosphate and cancer , 2010, Nature Reviews Cancer.

[15]  M. Cabot,et al.  Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase , 2010, Journal of Lipid Research.

[16]  M. Cabot,et al.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signaling , 2010, Molecular Cancer.

[17]  Jiawang Liu,et al.  Novel d-erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics , 2010, Cancer Chemotherapy and Pharmacology.

[18]  M. Cabot,et al.  A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis , 2009, PloS one.

[19]  Jiawang Liu,et al.  Design, synthesis, and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. , 2009, Journal of medicinal chemistry.

[20]  A. Melendez,et al.  Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. , 2009, Journal of medicinal chemistry.

[21]  A. Giuliano,et al.  A role for ceramide in driving cancer cell resistance to doxorubicin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[23]  S. Saddoughi,et al.  Roles of bioactive sphingolipids in cancer biology and therapeutics. , 2008, Sub-cellular biochemistry.

[24]  Ming Zhao,et al.  Dual-acting agents that possess reversing resistance and anticancer activities: Design, synthesis, MES-SA/Dx5 cell assay, and SAR of Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo[3',4':1,2]pyridin[3,4-b]indol-2-substitutedacetates. , 2007, Bioorganic & medicinal chemistry.

[25]  M. Cabot,et al.  Glycosphingolipids and drug resistance. , 2006, Biochimica et biophysica acta.

[26]  A. Llebaria,et al.  Inhibitors of sphingolipid metabolism enzymes. , 2006, Biochimica et biophysica acta.

[27]  W. Kamps,et al.  PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy , 2006, Molecular Cancer Therapeutics.

[28]  A. Giuliano,et al.  Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. , 2005, Cancer research.

[29]  Yan Tang,et al.  Novel Ceramide Analogs as Potential Chemotherapeutic Agents in Breast Cancer , 2004, Journal of Pharmacology and Experimental Therapeutics.

[30]  R. Bittman,et al.  Synthesis of New Trans Double-Bond Sphingolipid Analogues: Δ4,6 and Δ6 Ceramides , 2002 .

[31]  W. Kamps,et al.  1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  K. M. Nicholson,et al.  Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase , 1999, British Journal of Cancer.

[33]  S. Hakomori,et al.  In vitro and in vivo induction of apoptosis by sphingosine and N, N-dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.